John B Miller, Alison W Rebman, Marcia Daniela Villegas de Flores, Hong Wang, Erika Darrah, John N Aucott
{"title":"治疗后莱姆病中的附录素 A2 抗体。","authors":"John B Miller, Alison W Rebman, Marcia Daniela Villegas de Flores, Hong Wang, Erika Darrah, John N Aucott","doi":"10.1177/20499361241242971","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).</p><p><strong>Objectives: </strong>Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.</p><p><strong>Design and methods: </strong>Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.</p><p><strong>Results: </strong>Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 <i>versus</i> 48.22 units, <i>p</i> < 0.0001), though with no difference in total symptom burden.</p><p><strong>Conclusion: </strong>Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"11 ","pages":"20499361241242971"},"PeriodicalIF":3.8000,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981857/pdf/","citationCount":"0","resultStr":"{\"title\":\"Annexin A2 antibodies in post-treatment Lyme disease.\",\"authors\":\"John B Miller, Alison W Rebman, Marcia Daniela Villegas de Flores, Hong Wang, Erika Darrah, John N Aucott\",\"doi\":\"10.1177/20499361241242971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).</p><p><strong>Objectives: </strong>Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.</p><p><strong>Design and methods: </strong>Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.</p><p><strong>Results: </strong>Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 <i>versus</i> 48.22 units, <i>p</i> < 0.0001), though with no difference in total symptom burden.</p><p><strong>Conclusion: </strong>Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.</p>\",\"PeriodicalId\":46154,\"journal\":{\"name\":\"Therapeutic Advances in Infectious Disease\",\"volume\":\"11 \",\"pages\":\"20499361241242971\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981857/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Infectious Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20499361241242971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361241242971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Annexin A2 antibodies in post-treatment Lyme disease.
Background: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).
Objectives: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.
Design and methods: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.
Results: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.
Conclusion: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
